Literature DB >> 12893749

Functional defects of dendritic cells in patients with CD40 deficiency.

Stefania Fontana1, Daniele Moratto, Surinder Mangal, Maria De Francesco, William Vermi, Simona Ferrari, Fabio Facchetti, Necil Kutukculer, Claudia Fiorini, Marzia Duse, Pranab K Das, Luigi D Notarangelo, Alessandro Plebani, Raffaele Badolato.   

Abstract

We have recently identified 2 patients with a rare autosomal recessive form of hyper IgM disease, known as HIGM3, caused by mutations in the CD40 gene. These patients had opportunistic infections observed on X-linked hyper IgM syndrome (HIGM), suggesting that the CD40-CD40 ligand interaction is important for promoting T-cell-mediated immunity. To evaluate whether innate immunity signals may substitute CD154 for inducing the maturation of dendritic cells (DCs), we analyzed monocyte-derived DCs in these patients. Monocyte-derived DCs of HIGM3 subjects on ex vivo stimulation with tumor necrosis factor-alpha (TNF-alpha) or lipopolysaccharide (LPS) combined with interferon-gamma (IFN-gamma) normally express all the markers of mature DCs, such as CD83 and DC-LAMP. However, cell surface levels of HLA-DR in mature DCs are reduced, as is costimulatory activity of these cells for allogeneic naive T cells. In addition, CD40-deficient DCs secrete lower amounts of interleukin-12 (IL-12) but larger quantities of IL-10 than control subjects. Finally, analysis of circulating plasmacytoid DCs demonstrates a normal percentage of this subset in CD40-deficient cells, but IFN-alpha secretion in response to herpes simplex virus 1 (HSV-1) infection is severely reduced in patients. These observations suggest that the severe impairment of DC maturation may contribute to the defect of T-cell-mediated immunity observed in HIGM3 patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12893749     DOI: 10.1182/blood-2003-04-1244

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  16 in total

1.  Failure of HIV-exposed CD4+ T cells to activate dendritic cells is reversed by restoration of CD40/CD154 interactions.

Authors:  Rui Zhang; Jeffrey D Lifson; Claire Chougnet
Journal:  Blood       Date:  2005-11-03       Impact factor: 22.113

2.  Immunodeficiencies due to defects of class-switch recombination.

Authors:  Luigi D Notarangelo; Gaetana Lanzi; Paola Toniati; Silvia Giliani
Journal:  Immunol Res       Date:  2007       Impact factor: 2.829

Review 3.  Clinical, immunological, and molecular characterization of hyper-IgM syndrome due to CD40 deficiency in eleven patients.

Authors:  Bandar K Al-Saud; Zobaida Al-Sum; Hanadi Alassiri; Abdulaziz Al-Ghonaium; Saleh Al-Muhsen; Hasan Al-Dhekri; Rand Arnaout; Osama Alsmadi; Esteban Borrero; Asm'a Abu-Staiteh; Faisal Rawas; Hamoud Al-Mousa; Abbas Hawwari
Journal:  J Clin Immunol       Date:  2013-11       Impact factor: 8.317

4.  First report of the Hyper-IgM syndrome Registry of the Latin American Society for Immunodeficiencies: novel mutations, unique infections, and outcomes.

Authors:  Otavio Cabral-Marques; Stefanie Klaver; Lena F Schimke; Évelyn H Ascendino; Taj Ali Khan; Paulo Vítor Soeiro Pereira; Angela Falcai; Alexander Vargas-Hernández; Leopoldo Santos-Argumedo; Liliana Bezrodnik; Ileana Moreira; Gisela Seminario; Daniela Di Giovanni; Andrea Gómez Raccio; Oscar Porras; Cristina Worm Weber; Janaíra Fernandes Ferreira; Fabiola Scancetti Tavares; Elisa de Carvalho; Claudia França Cavalcante Valente; Gisele Kuntze; Miguel Galicchio; Alejandra King; Nelson Augusto Rosário-Filho; Milena Baptistella Grota; Maria Marluce dos Santos Vilela; Regina Sumiko Watanabe Di Gesu; Simone Lima; Leiva de Souza Moura; Eduardo Talesnik; Eli Mansour; Pérsio Roxo-Junior; Juan Carlos Aldave; Ekaterine Goudouris; Fernanda Pinto-Mariz; Laura Berrón-Ruiz; Tamara Staines-Boone; Wilmer O Córdova Calderón; María del Carmen Zarate-Hernández; Anete S Grumach; Ricardo Sorensen; Anne Durandy; Troy R Torgerson; Beatriz Tavares Costa Carvalho; Francisco Espinosa-Rosales; Hans D Ochs; Antonio Condino-Neto
Journal:  J Clin Immunol       Date:  2014-01-09       Impact factor: 8.317

5.  CD40 ligand deficiency causes functional defects of peripheral neutrophils that are improved by exogenous IFN-γ.

Authors:  Otavio Cabral-Marques; Tabata Takahashi França; Ashraf Al-Sbiei; Lena Friederike Schimke; Taj Ali Khan; Claudia Feriotti; Tania Alves da Costa; Osvaldo Reis Junior; Cristina Worm Weber; Janaíra Fernandes Ferreira; Fabiola Scancetti Tavares; Claudia Valente; Regina Sumiko Watanabe Di Gesu; Asif Iqbal; Gabriela Riemekasten; Gustavo Pessini Amarante-Mendes; José Alexandre Marzagão Barbuto; Beatriz Tavares Costa-Carvalho; Paulo Vitor Soeiro Pereira; Maria J Fernandez-Cabezudo; Vera Lucia Garcia Calich; Luigi D Notarangelo; Troy R Torgerson; Basel K Al-Ramadi; Hans D Ochs; Antonio Condino-Neto
Journal:  J Allergy Clin Immunol       Date:  2018-03-05       Impact factor: 10.793

6.  A functional TNFRSF5 gene variant is associated with risk of lymphoma.

Authors:  Christine F Skibola; Alexandra Nieters; Paige M Bracci; John D Curry; Luz Agana; Danica R Skibola; Alan Hubbard; Nikolaus Becker; Martyn T Smith; Elizabeth A Holly
Journal:  Blood       Date:  2008-02-20       Impact factor: 22.113

7.  Levels of CD40 expression on dendritic cells dictate tumour growth or regression.

Authors:  G Murugaiyan; S Martin; B Saha
Journal:  Clin Exp Immunol       Date:  2007-05-04       Impact factor: 4.330

8.  Comparison of cytokine expressions in acute myocardial infarction and stable angina stages of coronary artery disease.

Authors:  Wenwen Yan; Siwan Wen; Lemin Wang; Qianglin Duan; Lin Ding
Journal:  Int J Clin Exp Med       Date:  2015-10-15

9.  CD40-CD40 ligand interactions promote trafficking of CD8+ T cells into the brain and protection against West Nile virus encephalitis.

Authors:  Elizabeth Sitati; Erin E McCandless; Robyn S Klein; Michael S Diamond
Journal:  J Virol       Date:  2007-07-11       Impact factor: 5.103

Review 10.  Molecular basis and therapeutic implications of CD40/CD40L immune checkpoint.

Authors:  TingTing Tang; Xiang Cheng; Billy Truong; LiZhe Sun; XiaoFeng Yang; Hong Wang
Journal:  Pharmacol Ther       Date:  2020-10-20       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.